Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYELOCOURT: 3-day IV vs 3-day IV + 7-day oral antibiotics for acute pyelonephritis in young children
2024-518930-10-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ceftriaxone, amikacin, cefixime and trimethoprim + sulfamethoxazole in acute pyelonephritis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Nov 2024; status: authorised.
02
Drugs
ceftriaxoneamikacincefiximetrimethoprim + sulfamethoxazole
03
Conditions
acute pyelonephritis
Beyond the preview
Go deeper on 2024-518930-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518930-10-00.